← All trials
NCT04979572
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 16, 2021
- Primary completion
- Feb 28, 2022
- Completion date
- Mar 31, 2022
- First posted
- Jul 28, 2021
- Last posted
- Aug 24, 2021
- Enrollment
- 41
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Taisho PharmaceuticalLead sponsor
- Taisho PharmaceuticalStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.